Structure-function relationship between the human chemokine receptor CXCR3 and its ligands

被引:154
作者
Clark-Lewis, I
Mattioli, I
Gong, JH
Loetscher, P
机构
[1] Univ British Columbia, Ctr Biomed Res, Vancouver, BC V6T 1Z3, Canada
[2] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada
[3] Univ Bern, Theodor Kocher Inst, CH-3000 Bern, Switzerland
关键词
D O I
10.1074/jbc.M209470200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
I-TAC, IP10, and Mig are interferon-gamma inducible CXC chemokines that share the same G-protein-coupled receptor CXCR3, which is preferentially expressed on Th1 lymphocytes. We have explored the structure-function relationship of the CXCR3 ligands, in particular of I-TAC, which has highest affinity for CXCR3 and is the most potent agonist. A potent antagonist for CXCR3 was obtained by NH2-terminal truncation of I-TAC. I-TAC (4-73), which lacks the first three residues, has no agonistic activity but competes for the binding of I-TAC to CXCR3-bearing cells and inhibits migration and Ca2+ changes in such cells in response to stimulation with I-TAC, IP10, and Mig. It does also not induce internalization of CXCR3, which is in support of the lack of agonistic effects. Hybrid chemokines between I-TAC and IP10 were used to identify regions responsible for the higher activity of I-TAC. I-TAC-like IP10 analogs are obtained by substituting the NH2 terminus (residues 1-8) or N-loop region (residues 12-17) of IP10 with those of I-TAC, suggesting that the differences in function of the CXCR3 ligands can be assigned to distinct regions and that these regions are interchangeable. Structure-activity studies with Mig showed that the extended basic COOH-terminal region, which is not present in I-TAC and IP10, is important for binding and activity.
引用
收藏
页码:289 / 295
页数:7
相关论文
共 69 条
[1]
Agostini C, 1998, J IMMUNOL, V161, P6413
[2]
HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication [J].
Amara, A ;
LeGall, S ;
Schwartz, O ;
Salamero, J ;
Montes, M ;
Loetscher, P ;
Baggiolini, M ;
Virelizier, JL ;
ArenzanaSeisdedos, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :139-146
[3]
HIV blocked by chemokine antagonist [J].
ArenzanaSeisdedos, F ;
Virelizier, JL ;
Rousset, D ;
ClarkLewis, I ;
Loetscher, P ;
Moser, B ;
Baggiolini, M .
NATURE, 1996, 383 (6599) :400-400
[4]
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[5]
Blocking chemokine receptors [J].
Baggiolini, M ;
Moser, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) :1189-1191
[6]
Human chemokines: An update [J].
Baggiolini, M ;
Dewald, B ;
Moser, B .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :675-705
[7]
CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].
Balashov, KE ;
Rottman, JB ;
Weiner, HL ;
Hancock, WW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878
[8]
Blanpain C, 1999, BLOOD, V94, P1899
[9]
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[10]
The CXCR3 binding chemokine IP-10/CXCL10: Structure and receptor interactions [J].
Booth, V ;
Keizer, DW ;
Kamphuis, MB ;
Clark-Lewis, I ;
Sykes, BD .
BIOCHEMISTRY, 2002, 41 (33) :10418-10425